Search

This research focused on comparing the effects of Securinega virosa leaf extract and its partitioned fractions against methicillin-resistant Staphylococcus aureus (MRSA). The extraction process utilized 80% methanol, and the resulting crude extract underwent phytochemical screening using established protocols. Antimicrobial potency of the crude methanol extract and its aqueous and chloroform fractions was assessed using the agar well diffusion method. Additionally, their minimum inhibitory concentrations were determined. The phytochemical analysis revealed that the leaf extract of S. virosa contained various bioactive compounds, including alkaloids, flavonoids, saponins, steroids, tannins, terpenes, cardiac glycosides, anthraquinones, and reducing sugars. When tested for antibacterial activity, the crude extract at concentrations of 100, 50, 25, 12.5, and 6.25 mg/ml produced inhibition zones averaging 14.67 ± 0.82, 10.33 ± 0.82, 8.33 ± 0.41, 6.67 ± 0.41, and 4.33 ± 0.82 mm, respectively. For the partitioned fractions, the aqueous extract yielded inhibition zones of 10.50 ± 0.35, 6.67 ± 1.47, 4.67 ± 0.82, 1.67 ± 2.04, and 1.33 ± 1.63 mm across the same concentrations. The chloroform fraction resulted in inhibition zones of 10.33 ± 1.08, 6.67 ± 0.41, 4.33 ± 1.08, and 2.66 ± 1.78 mm, respectively.Regarding the minimum inhibitory concentration, the crude extract displayed effectiveness starting at 25 mg/ml, while both the aqueous and chloroform fractions showed inhibitory activity at 50 mg/ml. Overall, all forms of S. virosa extracts tested (crude methanol, aqueous, and chloroform) demonstrated activity against MRSA, with the crude extract exhibiting the most pronounced antibacterial effect.

This article focuses on examining the structure of microorganisms and their antimicrobial drug resistance during the provision of in-hospital medical care for patients with COVID-19. Among monotypic fungal infections, Candida albicans predominated at 46.82% (n = 375), followed by Candida glabrata at 21.97% (n = 176). Streptococcus pneumoniae accounted for 25.24% (n = 617), while the combined antimicrobial presence of S. pneumoniae with Candida species represented 11.17% (n = 273), ranking highest in isolation frequency among all microorganisms. In deceased patients, the dominant pathogens identified were Klebsiella pneumoniae at 36.3% (n = 159) and Candida fungi at 21.92% (n = 96). Analysis of antimicrobial resistance revealed that S. pneumoniae (n=890) exhibited low resistance rates to benzylpenicillin (4.2%, n = 37), levofloxacin (11.5%, n = 102), and linezolid (0%), but showed elevated resistance to erythromycin (27.4%, n = 244), lincomycin (25.2%, n = 224), and doxycycline (15.5%, n = 141). The vast majority of K. pneumoniae isolates (n = 326) demonstrated resistance to ampicillin (97.9%), cefuroxime (94.2%), cefotaxime (87.7%), ceftazidime (85%), and cefepime (73%), with comparatively lower resistance to amoxicillin-clavulanic acid (52.1%, n = 170) and meropenem (33.4%, n = 109). Microorganisms exhibiting pan-drug resistance accounted for 7.6% (n = 125) of isolates, with the highest proportion of PDR strains attributed to K. pneumoniae, comprising 33.4% (n = 109) of all Klebsiella isolates. C. albicans and S. pneumoniae are the most frequently isolated pathogens among COVID-19 patients receiving inpatient care. The rising detection of extensively drug-resistant (XDR) and pan-drug-resistant (PDR) Klebsiella spp. underscores the critical need for careful selection of empirical antibacterial therapies.

The chemistry of α-(arylhydrazono)-β-ketoaldehydes has attracted significant attention due to their use as intermediates in organic synthesis and as building blocks for biologically active compounds. This study presents the synthesis of a novel series of 3,3'-(5-methyl-1-phenyl-1H-pyrazole-3,4-diyl)bis(2-arylhydrazono-3-oxo-propanal) (3a-i), created through coupling reactions of sodium 3,3'-(5-methyl-1-phenyl-1H-pyrazole-3,4-diyl)bis(3-oxoprop-1-en-1-olate) (2) with arenediazonium chloride. The subsequent condensation of these compounds 3a-i with hydrazine hydrate produced a new series of bis(arylazo)-terpyrazole derivatives (5a-i). The new compounds were characterized using spectroscopic techniques and basic evaluations. Furthermore, the electronic absorption spectra of the compounds were recorded in various buffer solutions, and their acidity constants (pK) were calculated. The study also examined the correlation between these constants and Hammett substituent constants. Results indicated that the compounds predominantly exist in the bis-hydrazo form (5A). Compounds 5a-i were evaluated for their antibacterial and anticancer properties against the HepG2 cell line in vitro.

Microorganisms are the primary triggers of various inflammatory diseases in the human body. Diseases such as bronchitis, otitis media, pneumonia, conjunctivitis, cystitis, endometritis, and infections of the fallopian tubes and ovaries are routinely treated with antimicrobial agents in global medical protocols. Bacterial infections like chlamydia, streptodermia, scarlet fever, meningitis, and tuberculosis cannot be treated without the application of antimicrobial therapies. Likewise, viral conditions such as herpes, chickenpox, hepatitis C and B, and HIV are now addressed using antiviral treatments. Antibiotics are used to treat fungal infections of the skin, mucous membranes, and nails, as well as systemic mycoses. For protozoal diseases such as giardiasis, amoebic dysentery, trichomoniasis, malaria, and toxoplasmosis, antiprotozoal drugs are prescribed. These therapeutic agents target a wide range of pathogens, including bacteria, viruses, fungi, and protozoa. This article offers a succinct review of various antimicrobial drugs and provides an in-depth analysis of the Russian antimicrobial drug market.